PT Kedoya Adyaraya (RSGK) Fundamentals 2026 — P/E 26.1x, Revenue Analysis | SniperIQ
PT Kedoya Adyaraya (RSGK) is a ID-listed Healthcare company in Medical - Care Facilities with a market capitalization of Rp929.7B, trading at Rp1000.00 on the JKT. This SniperIQ fundamentals page covers PT Kedoya Adyaraya's valuation (P/E 26.1x, P/B 1.1x), profitability (net margin 7.3%), revenue (Rp469.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Kedoya Adyaraya's market cap?
PT Kedoya Adyaraya (RSGK) has a market capitalization of approximately Rp929.7B, trading at Rp1000.00 on the JKT. Market cap moves with the live share price.
What is PT Kedoya Adyaraya's P/E ratio?
PT Kedoya Adyaraya's trailing twelve-month P/E ratio is 26.1x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Kedoya Adyaraya?
PT Kedoya Adyaraya runs a net profit margin of 7.3%, a gross margin of 29.7%, and an operating margin of 9.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Kedoya Adyaraya generate?
PT Kedoya Adyaraya reported revenue of Rp469.6B for fiscal year 2025, with net income of Rp34.5B and earnings per share (EPS) of 37.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Kedoya Adyaraya pay a dividend?
PT Kedoya Adyaraya does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PT Kedoya Adyaraya financially healthy?
PT Kedoya Adyaraya carries a debt-to-equity ratio of 0.00x and a current ratio of 1.22x, with a market beta of -0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Kedoya Adyaraya a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Kedoya Adyaraya (RSGK) the key facts are: market cap Rp929.7B, P/E 26.1x, revenue Rp469.6B, 52-week range 610-1560. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Kedoya Adyaraya's full fundamentals live
Get PT Kedoya Adyaraya's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.